The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending Approval Of Merck's Keytruda In Combination With Padcev (Enfortumab Vedotin) For The First-line Treatment Of Unresectable Or Metastatic
The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending Approval Of Merck's Keytruda In Combination With Padcev (Enfortumab Vedotin) For The First-line Treatment Of Unresectable Or Metastatic
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.